Clinical and immunomorphological predictors of the adverse course of chronic hepatitis C
https://doi.org/10.22625/2072-6732-2020-12-2-79-87
Abstract
Wide incidence and high rate of poor outcomes of viral hepatitis C makes this issue very important. In majority of cases viral hepatitis C develops chronic form of the disease resulting in fibrosis, cirrhosis and hepatocellular carcinoma in longstanding period of time. The specificity of clinical presentation and particular aspects of pathogenesis complicates making the prognosis of its course significantly.
Objective. Estimation of clinical and immunomorphological factors that influence the process of fibrogenesis in chronic hepatitis C.
Material and methods. The object of our research was 64 liver biopsy samples from adults with natural course of chronic hepatitis C. Using immunohistochemistry and morphometric method intrahepatic CD3+, CD8+Т-lymphocites, CD68+-macrophages, alfa-SMA+-stellate cells were counted. Then the connection between this markers and histological activity index (HAI), stage of fibrosis, ALT elevation, viral load and viral genotype were evaluated.
Results. It was established, that increasing amount of intrahepatic CD8+-lymphocytes implicates augmentation of histological activity and ALT level: CD8 abs./HAI – r=0,56; CD8 abs/ALT – r=0,45; HAI/ALT – r=0,58 (p<0,05), and also raising of CD68+-macrophages in mild and moderate HAI: СD8 абс./СD68 абс. – r=0,58 и 0,54 accordingly (p<0,05), and alfa-SMA+-stellate cells. Histological activity was prone to raise with the stage of fibrosis. Also the higher number of intrahepatic CD8+-lymphocytes, HAI and ALT elevation was identified in cases with viral genotype 3.
Conclusion. As a result, unfavorable implication of cellrelated immune lesion and viral genotype 3 in fibrosis progression was demonstrated. The role of viral load was ambiguous.
About the Authors
I. A. Karabak
Pediatric Research and Clinical Center for Infectious Diseases
Russian Federation
Saint-Petersburg
Russian Federation
Saint-Petersburg
D. Yu. Lobzin
Pediatric Research and Clinical Center for Infectious Diseases;
Military Medical Academy named after S.M. Kirov
Russian Federation
Saint-Petersburg
Russian Federation
Saint-Petersburg
V. E. Karev
Pediatric Research and Clinical Center for Infectious Diseases
Russian Federation
Saint-Petersburg
Russian Federation
Saint-Petersburg
References
1. Kwon Y.-C. Hepatitis C virus infection: establishment of chronicity and liver disease progression / Kwon Y.-C., Ray R.B., Ray R. // EXCLI journal – 2014. – Т. 13 – Р.977.
2. Organization W.H. Guidelines for the Screening Care and Treatment of Persons with Chronic Hepatitis C Infection / Organization W.H. // Guidelines for the Screening Care and Treatment of Persons with Chronic Hepatitis C Infection: Updated Version – 2016. – № April.
3. Sebastiani G. Chronic hepatitis C and liver fibrosis / Sebastiani G., Gkouvatsos K., Pantopoulos K. // World Journal of Gastroenterology – 2014. – Т. 20 – № 32 – Р.11033–11053.
4. Shi J. Current progress in host innate and adaptive immunity against hepatitis C virus infection / Shi J., Li Y., Chang W., Zhang X., Wang F.S. // Hepatology International – 2017. – Т. 11 – № 4 – Р.374–383.
5. Zhang C.-Y. Liver fibrosis and hepatic stellate cells: Etiology, pathological hallmarks and therapeutic targets. / Zhang C.- Y., Yuan W.-G., He P., Lei J.-H., Wang C.-X. // World journal of gastroenterology – 2016. – Т. 22 – № 48 – Р.10512–10522.
6. Karev, V.E. Clinical and immunomorphological aspects of pathogenesis of chronic HBV- and HCV infection: autoref. diss.doct.med.nauk/ V.E.Karev. – SPb, 2016. – 40p.
7. Westbrook R.H. Natural history of hepatitis C / Westbrook R.H., Dusheiko G. // Journal of Hepatology – 2014. – Т. 61 – № 1 – Р.S58–S68.
8. European Association for Study of Liver and others. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. / European Association for Study of Liver and others. // Journal of hepatology – 2014. – Т. 60 – № 2 – Р.392.
9. Ivashkin V.T. Immune system and lesion of liver at chronic hepatitis B and C/ Ivashkin V.T. // Russian journal of gastroenterology, hepatology, coloproctology – 2009. – T.19 – № 6 – p.4-10
10. Wong G.L.-H. Prediction of fibrosis progression in chronic viral hepatitis / Wong G.L.-H. // Clinical and Molecular Hepatology – 2014. – Т. 20 – № 3 – Р.228.
11. Lingala S. Natural History of Hepatitis C / Lingala S., Ghany M.G. // Gastroenterology Clinics of North America – 2015. – Т. 44 – № 4 – Р.717–734.
12. Shahnazarian V. Hepatitis C virus genotype 3: Clinical features, current and emerging viral inhibitors, future challenges / Shahnazarian V., Ramai D., Reddy M., Mohanty S. // Annals of Gastroenterology – 2018. – Т. 31 – № 5 – Р.541–551.
13. Bogdanos D.P. Liver immunology / Bogdanos D.P., Gao B., Gershwin M.E. // Comprehensive Physiology – 2013. – Т. 3 – № 2 – Р.567–598.
14. Lobzin Yu.V. Immunopathogenesis of viral hepatitis С Immunological markers of the disease progression/ Lobzin Yu.V., Nikitin V.Yu., Sukhina L.A., Tsigan V.N., Mitin Yu.A// Journal of microbiology, epidemiology and immunopatology – 2007. – № 6 – р.75-84.
15. Boltjes A. The role of Kupffer cells in hepatitis B and hepatitis C virus infections / Boltjes A., Movita D., Boonstra A., Woltman A.M. // Journal of Hepatology – 2014. – Т. 61 – № 3 – Р.660–671.
16. Heydtmann M. Macrophages in Hepatitis B and Hepatitis C Virus Infections / Heydtmann M. // Journal of Virology – 2008. – Т. 83 – № 7 – Р.2796–2802.
17. Elpek G.Ö. Cellular and molecular mechanisms in the pathogenesis of liver fibrosis: An update / Elpek G.Ö. // World Journal of Gastroenterology – 2014. – Т. 20 – № 23 – Р.7260–7276.
18. Bedossa P. An algorithm for the grading of activity in chronic hepatitis C / Bedossa P., Poynard T. // Hepatology – 1996. – Т. 24 – № 2 – Р.289–293.
19. McCormick S.E. Evaluation of liver histology, ALT elevation, and HCV RNA titer in patients with chronic hepatitis C. / McCormick S.E., Goodman Z.D., Maydonovitch C.L., Sjogren M.H. // American Journal of Gastroenterology – 1996. – Т. 91 – № 8.
20. Moliner L. De Serum and liver HCV RNA levels in patients with chronic hepatitis C : correlation with clinical and histological features / Moliner L. De, Pontisso P., Salvo G.L. De, Cavalletto L., Chemello L., Alberti A. – 1998. – Р.856–860.
21. Ghany M.G. Correlation between serum HCV RNA and aminotransferase levels in patients with chronic HCV infection / Ghany M.G., Chan T.M., Sanchez-Pescador R., Urdea M., Lok A.S.F. // Digestive Diseases and Sciences – 1996. – Т. 41 – № 11 – Р.2213–2218.
22. Vinaixa C. Disease Reversibility in Patients With PostHepatitis C Cirrhosis / Vinaixa C., Strasser S.I., Berenguer M. // Transplantation – 2017. – Т. 101 – № 5 – Р.916–923.
23. D’Ambrosio R. Should surveillance for liver cancer be modified in hepatitis C patients after treatment-related cirrhosis regression? / D’Ambrosio R., Colombo M. // Liver International – 2016. – Т. 36 – № 6 – Р.783–790.
24. Mallet V. Annals of Internal Medicine Article Brief Communication : The Relationship of Regression of Cirrhosis to / Mallet V. – 2008. – Р.399–404.
25. Li H. Hepatitis C: From inflammatory pathogenesis to anti-inflammatory/hepatoprotective therapy. / Li H., Huang M.-H., Jiang J.-D., Peng Z.-G. // World journal of gastroenterology – 2018. – Т. 24 – № 47 – Р.5297–5311.
26. Sysoev K.A. Cytokines and chemokines in the blood plasma of patients with chronic hepatitis C. / Sysoev K.A., Chukhlovin A.B., Shakhmanov D.M., Zhdanov K.V., Totolian Areg A. // Infection and immunity – 2013. – T.3 – № 1.
Review
For citations:
Karabak I.A., Lobzin D.Yu., Karev V.E. Clinical and immunomorphological predictors of the adverse course of chronic hepatitis C. Journal Infectology. 2020;12(2):79-87. (In Russ.) https://doi.org/10.22625/2072-6732-2020-12-2-79-87
Views:
836
.png)
.png)
Email this article 